References
- Bonnet D., Dick J.E.: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3, 730–737, doi: 10.1038/nm0797-730.
- Boughey J.C., Gonzalez R.J., Bonner E., Kuerer H.M.: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12, 1276–1287, doi: 10.1634/theoncologist.12-11-1276.
- Caceres S., Pena L., de Andres P.J., Illera M.J., Lopez M.S., Woodward W.A., Reuben J.M., Illera J.C.: Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One 2015, 10, e0122277, doi: 10.1371/journal.pone.0122277.
- Caceres S., Pena L., Lacerda L., Illera M.J., de Andres P.J., Larson R.A., Gao H., Debeb B.G., Woodward W.A., Reuben J.M., Illera J.C.: Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer. Vet Comp Oncol 2017, 15, 980–995, doi: 10.1111/vco.12238.
- de Mello Souza C.H., Toledo-Piza E., Amorin R., Barboza A., Tobias K.M.: Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J 2009, 50, 506–510.
- Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555–567, doi: 10.1016/j.stem.2007.08.014.
- Hance K.W., Anderson W.F., Devesa S.S., Young H.A., Levine P.H.: Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005, 97, 966–975, doi: 10.1093/jnci/dji172.
- Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., Masuko T., Shimizu T., Ishikawa T., Kai K., Takahashi E., Imamura Y., Baba Y., Ohmura M., Suematsu M., Baba H., Saya H.: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19, 387–400, doi: 10.1016/j.ccr.2011.01.038.
- Jergens A.E., Schreiner C.A., Frank D.E., Niyo Y., Ahrens F.E., Eckersall P.D., Benson T.J., Evans R.: A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003, 17, 291–297, doi: 10.1111/j.1939-1676.2003.tb02450.x.
- Kurebayashi J., Yamamoto S., Otsuki T., Sonoo H.: Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 1999, 79, 631–636, doi: 10.1038/sj.bjc.6690099.
- Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., Helyer L., Pan L., Leidal A., Gujar S., Giacomantonio C.A., Lee P.W.: Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29, 32–45, doi: 10.1002/stem.563.
- Maruo T., Kanemaki N., Onda K., Sato R., Ichihara N., Ochiai H.: Canine amino acid transport system Xc(-): cDNA sequence, distribution and cystine transport activity in lens epithelial cells. J Vet Med Sci 2014, 76, 523–530, doi: 10.1292/jvms.13-0170.
- Michishita M., Akiyoshi R., Suemizu H., Nakagawa T., Sasaki N., Takemitsu H., Arai T., Takahashi K.: Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J 2012, 193, 508–513, doi: 10.1016/j.tvjl.2012.01.006.
- Michishita M., Akiyoshi R., Yoshimura H., Katsumoto T., Ichikawa H., Ohkusu-Tsukada K., Nakagawa T., Sasaki N., Takahashi K.: Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines. Res Vet Sci 2011, 91, 254–260, doi: 10.1016/j.rvsc.2010.11.016.
- Moreb J.S.: Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008, 3, 237–246, doi: 10.2174/ 157488808786734006.
- Mu Z., Klinowska T., Dong X., Foster E., Womack C., Fernandez S.V., Cristofanilli M.: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res 2014, 33, 47, doi: 10.1186/1756-9966-33-47.
- Nishikawa S., Konno M., Hamabe A., Hasegawa S., Kano Y., Ohta K., Fukusumi T., Sakai D., Kudo T., Haraguchi N., Satoh T., Takiguchi S., Mori M., Doki Y., Ishii H.: Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol 2013, 42, 1437–1442, doi: 10.3892/ijo.2013.1837.
- Okazaki S., Shintani S., Hirata Y., Suina K., Semba T., Yamasaki J., Umene K., Ishikawa M., Saya H., Nagano O.: Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. Oncotarget 2018, 9, 33832–33843, doi: 10.18632/oncotarget.26112.
- Otsubo K., Nosaki K., Imamura C.K., Ogata H., Fujita A., Sakata S., Hirai F., Toyokawa G., Iwama E., Harada T., Seto T., Takenoyama M., Ozeki T., Mushiroda T., Inada M., Kishimoto J., Tsuchihashi K., Suina K., Nagano O., Saya H., Nakanishi Y., Okamoto I.: Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer Sci 2017, 108, 1843–1849, doi: 10.1111/cas.13309.
- Perez Alenza M.D., Tabanera E., Pena L.: Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001, 219, 1110–1114, doi: 10.2460/javma.2001.219.1110.
- Reya T., Morrison S.J., Clarke M.F., Weissman I.L.: Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105–111, doi: 10.1038/35102167.
- Ruiu R., Rolih V., Bolli E., Barutello G., Riccardo F., Quaglino E., Merighi I.F., Pericle F., Donofrio G., Cavallo F., Conti L.: Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. Cancer Immunol Immunother 2019, 68, 131–141, doi: 10.1007/s00262-018-2185-1.
- Sharma M.K., Seidlitz E.P., Singh G.: Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun 2010, 391, 91–95, doi: 10.1016/j.bbrc.2009.10.168.
- Shirakawa K., Tsuda H., Heike Y., Kato K., Asada R., Inomata M., Sasaki H., Kasumi F., Yoshimoto M., Iwanaga T., Konishi F., Terada M., Wakasugi H.: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001, 61, 445–451.
- Sun S., Wang Z.: ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem Biophys Res Commun 2010, 396, 843–848, doi: 10.1016/j.bbrc.2010.04.170.
- Tanabe A., Kimura K., Tazawa H., Maruo T., Taguchi M., Sahara H.: Functional analysis of CD44 variants and xCT in canine tumours. Vet Med Sci 2021, 7, 577–585, doi: 10.1002/vms3.397.
- Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van ’t Veer L.J., Polyak K., McCormick F., Gray J.W.: Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013, 24, 450–465, doi: 10.1016/j.ccr.2013.08.020.
- Uyama R., Nakagawa T., Hong S.H., Mochizuki M., Nishimura R., Sasaki N.: Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol 2006, 4, 104–113, doi: 10.1111/j.1476-5810.2006.00098.x.
- Van den Eynden G.G., Van Laere S.J., Van der Auwera I., Merajver S.D., Van Marck E.A., van Dam P., Vermeulen P.B., Dirix L.Y., van Golen K.L.: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006, 95, 219–228, doi: 10.1007/s10549-005-9002-1.
- Vassalli G.: Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells. Stem Cells Int 2019, 2019, 3904645, doi: 10.1155/2019/3904645.
- Visvader J.E., Stingl J.: Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev 2014, 28, 1143–1158, doi: 10.1101/gad.242511.114.
- Xiao Y., Ye Y., Yearsley K., Jones S., Barsky S.H.: The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 2008, 173, 561–574, doi: 10.2353/ajpath.2008.071214.
- Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G.J., Wada T., Masuko T., Mogushi K., Tanaka H., Osawa T., Kanki Y., Minami T., Aburatani H., Ohmura M., Kubo A., Suematsu M., Takahashi K., Saya H., Nagano O.: Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012, 3, 883, doi: 10.1038/ncomms1892.
- Yamauchi H., Woodward W.A., Valero V., Alvarez R.H., Lucci A., Buchholz T.A., Iwamoto T., Krishnamurthy S., Yang W., Reuben J.M., Hortobagyi G.N., Ueno N.T.: Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012, 17, 891–899, doi: 10.1634/theoncologist.2012-0039.
- Zhou Y., Yang J., Chen C., Li Z., Chen Y., Zhang X., Wang L., Zhou J.: Polyphyllin -Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT. Front Pharmacol 2021, 12, 670224, doi: 10.3389/fphar.2021.670224.